2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114325
    AcLysValCit-PABC-DMAE-SW-163D
    AcLysValCit-PABC-DMAE-SW-163D is a agent-linker conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker.
    AcLysValCit-PABC-DMAE-SW-163D
  • HY-163487
    Puxitatug samrotecan drug-linker
    		98.98%
    Puxitatug samrotecan drug-linker (AZD8205 drug-linker) is a drug-linker conjugate for ADC, which comprises a topoisomerase I inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesis antibody-drug conjugate (ADC), Puxitatug samrotecan (HY-171689).
    Puxitatug samrotecan drug-linker
  • HY-126492
    Vat-Cit-PAB-Monomethyl Dolastatin 10
    Vat-Cit-PAB-Monomethyl Dolastatin 10 is a agent-linker conjugate for ADC with potent antitumor activity by using Monomethyl Dolastatin 10 (a potent tubulin inhibitor), linked via the ADC linker Vat-Cit-PAB.
    Vat-Cit-PAB-Monomethyl Dolastatin 10
  • HY-136289
    MB-VC-MGBA
    MB-VC-MGBA is a agent-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC.
    MB-VC-MGBA
  • HY-112806
    ST8155AA1
    ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor. ST8155AA1 induces α-tubulin, histone H3/H4 acetylation via direct enzymatic inhibition. ST8155AA1 recognizes and binds EGFR, undergoes internalization into EGFR-expressing tumor cells. ST8155AA1 inhibits cancer cell proliferation and exerts activity in mouse tumor models. ST8155AA1 can be used for the research of non-small cell lung cancer.
    ST8155AA1
  • HY-145663
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety.
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
  • HY-128896
    Nitro-PDS-Tubulysin M
    Nitro-PDS-Tubulysin M is a synthetic ADC drug-linker conjugate composed of the tubulin polymerization inhibitor Tubulysin M (an ADC Cytotoxin) and Nitro-PDS (an ADC linker).
    Nitro-PDS-Tubulysin M
  • HY-128954
    Sulfo-PDBA-DM4
    Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.
    Sulfo-PDBA-DM4
  • HY-128893
    MC-Sq-Cit-PAB-Gefitinib
    MC-Sq-Cit-PAB-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
    MC-Sq-Cit-PAB-Gefitinib
  • HY-126692
    Mal-VC-PAB-ABAEP-Azonafide
    Mal-VC-PAB-ABAEP-Azonafide is a agent-linker conjugate for ADC with with potent antitumor activity by using Azonafide (a cytotoxin), linked via the ADC linker Mal-VC-PAB.
    Mal-VC-PAB-ABAEP-Azonafide
  • HY-128905
    MC-Val-Cit-PAB-dimethylDNA31
    		99.97%
    MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
    MC-Val-Cit-PAB-dimethylDNA31
  • HY-101909
    Val-Cit-PAB-MMAF
    Val-Cit-PAB-MMAF is a drug-Linker conjugate for ADC. Val-Cit-PAB-MMAF is composed of an ADC linker (peptide Val-Cit-PAB) and a potent microtubule polymerization inhibitor MMAF (HY-15579).
    Val-Cit-PAB-MMAF
  • HY-15578G
    McMMAF (GMP)
    McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent.
    McMMAF (GMP)
  • HY-145736A
    β-Glucuronide-dPBD-PEG5-NH2 TFA
    β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity.
    β-Glucuronide-dPBD-PEG5-NH2 TFA
  • HY-145736
    β-Glucuronide-dPBD-PEG5-NH2
    β-Glucuronide-dPBD-PEG5-NH2 is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD. β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 has antitumor activity.
    β-Glucuronide-dPBD-PEG5-NH2
  • HY-148812
    Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan
    Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan is used for ADC Synthesis.
    Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan
  • HY-171946
    TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
    TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT is a drug-linker conjugate for ADC. TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT consists of a topoisomerase 1 inhibitor (Topi MF-6) (HY-175203) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala) (HY-175218). TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT can be used for synthesis of ADCs.
    TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
  • HY-178290
    MC-Gly-Gly-Phe-Exatecan analog 38
    MC-Gly-Gly-Phe-Exatecan analog 38 (Compound L-II-4) is part of an antibody-drug conjugate (ADC), consisting of an ADC toxicant molecule and an ADC linker. MC-Gly-Gly-Phe-Exatecan analog 38 can be used to synthesize ADCs (such as ADC-II-15 and ADC-III-13). MC-Gly-Gly-Phe-Exatecan analog 38 can also be used in cancer research (ADC Cytotoxin: HY-178315, ADC Linker: HY-44235).
    MC-Gly-Gly-Phe-Exatecan analog 38
  • HY-164310
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF is a linker-drug conjugate, which is consisted of a click pair TCO, a spacer PEG, a cleavable linker Glu-Val-Cit, a PBAC group and a cytotoxin MMAF (HY-15579). TCO-PEG3-Glu-Val-Cit-PABC-MMAF can be used for synthesis of dual drug ADC.
    TCO-PEG3-Glu-Val-Cit-PABC-MMAF
  • HY-176926
    GDP-Fuc-AM-VcPAB-MMAE
    GDP-Fuc-AM-VcPAB-MMAE is a conjugate of toxic molecule Monomethyl auristatin E (MMAE) (HY-15162) and linkers. GDP-Fuc-AM-VcPAB-MMAE is an important precursor molecule that can be used to prepare ADC drugs. GDP-Fuc-AM-VcPAB-MMAE can be used for cancer research.
    GDP-Fuc-AM-VcPAB-MMAE
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.